Premium
Effects of Catechol‐ O ‐Methyltransferase Inhibitors and L‐3,4‐Dihydroxyphenylalanine With or Without Carbidopa on Extracellular Dopamine in Rat Striatum
Author(s) -
Kaakkola Seppo,
Wurtman Richard J.
Publication year - 1993
Publication title -
journal of neurochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.75
H-Index - 229
eISSN - 1471-4159
pISSN - 0022-3042
DOI - 10.1111/j.1471-4159.1993.tb05831.x
Subject(s) - homovanillic acid , carbidopa , chemistry , dopamine , catechol o methyl transferase , dihydroxyphenylalanine , striatum , 3,4 dihydroxyphenylacetic acid , pharmacology , endocrinology , medicine , levodopa , serotonin , biochemistry , parkinson's disease , allele , receptor , disease , gene
The effects of two new catechol‐ O ‐methyltransferase (COMT) inhibitors, OR‐611 and Ro 40‐7592, in combination with L‐3,4‐dihydroxyphenylalanine (L‐dopa) with or without carbidopa on extracellular levels of dopamine (DA), 3,4‐dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), 3‐ O ‐methyldopa (3‐OMD), and 5‐hydroxyindoleacetic acid in rat striatum were studied. A dose of 10 mg/kg i.p. of Ro 40‐7592 alone, in contrast to the same dose of OR‐611, decreased the dialysate level of HVA and increased that of DOPAC; this dose was thus used to differentiate between the effects of central and peripheral COMT inhibition. L‐Dopa (50 mg/kg i.p.) alone slightly increased extracellular levels of DA, DOPAC, and HVA. The effects of L‐dopa were potentiated by carbidopa (50 mg/kg i.p.), and even 3‐OMD levels in dialysate samples became detectable. Both OR‐611 and Ro 40‐7592 significantly further increased the DA and DOPAC efflux from striatum produced by L‐dopa. This increase was more pronounced when carbidopa was added to the treatment. OR‐611 did not modify the effect of L‐dopa or carbidopa/L‐dopa on dialysate HVA levels, whereas Ro 40‐7592 markedly reduced those levels. Both OR‐611 and Ro 40‐7592 very clearly suppressed dialysate 3‐OMD levels produced by carbidopa/L‐dopa. Ro 40‐7592 was more effective than OR‐611 in potentiating the effects of L‐dopa or carbidopa/L‐dopa. These in vivo data show that the new COMT inhibitors markedly inhibit the O ‐methylation of L‐dopa and increase its availability to brain, which is reflected as increased DA formation. A significant effect can be achieved even by inhibiting only the peripheral COMT activity. The data suggest that COMT inhibitors may be of clinical importance as adjuncts in the treatment of Parkinson's disease.